Peter Kolchinsky portfolio, Q2 2026

RA Capital Management · 13F for the quarter ending Jun 30, 2026

For Q2 2026, RA Capital Management reported $11.5B across 84 US-listed positions, led by ASND (23.8%), PBLS (6.9%) and RYTM (6.4%). Compared with its filing for Q1 2026, Peter Kolchinsky opened 16 new positions, added to 10, reduced 10 and sold out of 17; 47 positions did not change.

The largest purchase was a new position in PBLS ($791.9M); the largest sale, the sale of the whole position in DNTH ($219.2M).

This is the latest filing on file; the main portfolio page shows the same holdings against today's prices.

Reported value
$11.5B
Positions
84
In the top 10
60%
Filed
Aug 14
2026

Key facts

13F portfolio value
$11.5BQ2 2026
Positions
84
Largest holding
ASND 23.8%
New positions
16
Sold out
17
Filed
Aug 14, 2026

Holdings as of (Q2 2026), filed with the SEC on . Changes are measured against the filing for Mar 31, 2026. Every tracked investor's Q2 2026 13F.

Bought and sold in Q2 2026

Peter Kolchinsky: buys and sells in Q2 2026
StockMoveSharesSizeOf portfolio
Parabilis Medicines IncPBLS▲ New+28.93M$791.9M6.88%
Hemab Therapeutics HoldingsCOAG▲ New+7.81M$286.8M2.49%
Dianthus Therapeutics IncDNTH▼ Sold out−2.61M$219.2M1.90%
Nuvalent Incno ticker on file
▼ Reduced 51%−1.29M$159M1.38%
Abivax SAABVX▲ New+1.13M$150.9M1.31%
Oruka Therapeutics IncORKA▲ New+1.55M$148M1.29%
Praxis Precision MedicinesPRAX▼ Sold out−373.79K$120.4M1.05%
Sarepta Therapeutics IncSRPT▼ Sold out−3.9M$84.9M0.74%
Edgewise Therapeutics IncEWTX▼ Reduced 20%−2.04M$82.7M0.72%
Spyre Therapeutics IncSYRE▼ Sold out−1.62M$81.8M0.71%
Artiva Biotherapeutics IncARTV▲ Added 82%+8.1M$78.6M0.68%
Intellia Therapeutics IncNTLA▲ New+4.53M$76.6M0.67%
Definium Therapeutics IncDFTX▲ New+1.5M$70.6M0.61%
Sana Biotechnology IncSANA▲ New+18.75M$65.4M0.57%
Vor Biopharma IncVOR▼ Reduced 56%−3M$55.3M0.48%
Fulcrum Therapeutics IncFULC▼ Sold out−6.05M$46.4M0.40%
Olema Pharmaceuticals IncOLMA▼ Sold out−2.6M$38.8M0.34%
Prelude Therapeutics IncPRLD▲ New+6.48M$34.5M0.30%
Design Therapeutics IncDSGN▼ Sold out−2.97M$31.6M0.27%
Aclaris Therapeutics IncACRS▲ Added 87%+5.92M$31.3M0.27%
Q32 Bio IncQTTB▲ New+2.33M$29.7M0.26%
Editas Medicine IncEDIT▲ New+8.89M$28.8M0.25%
Solid Biosciences IncSLDB▲ Added 29%+2.7M$26.9M0.23%
Geron CorpGERN▼ Reduced 33%−20.96M$26.8M0.23%
Travere Therapeutics IncTVTX▼ Sold out−746.84K$22.2M0.19%
Grail IncGRAL▼ Sold out−428.27K$22.1M0.19%
Relmada Therapeutics IncRLMD▼ Sold out−2.95M$20.5M0.18%
Altimmune IncALT▲ New+6.5M$19.8M0.17%
Faeth Therapeutics IncFTH▲ New+722.02K$18.1M0.16%
Sutro Biopharma IncSTRO▼ Sold out−715.31K$17.8M0.15%
Aura Biosciences IncAURA▲ New+2.5M$17.8M0.15%
Contineum Therapeutics IncCTNM▼ Sold out−1.3M$16.9M0.15%
Inspire Med Systems IncINSP▼ Sold out−325.66K$16.8M0.15%
Seaport Therapeutics IncSPTX▲ New+700K$15.2M0.13%
Hinge Health IncHNGE▼ Sold out−364.61K$14.1M0.12%
GeneDx Holdings CorpWGS▼ Sold out−209.89K$13.5M0.12%
Atrium Therapeutics IncRNA▼ Sold out−864.1K$11.6M0.10%
Acrivon Therapeutics IncACRV▲ Added 47%+3.89M$6.9M0.06%
Avalo Therapeutics IncAVTX▲ Added 51%+337.03K$6.2M0.05%
Aktis Oncology IncAKTS▼ Reduced 13%−188.68K$6.1M0.05%
Xencor IncXNCR▲ Added 7.7%+377.04K$6.1M0.05%
Jatt II Acquisition CorpJATT▲ New+500K$5.7M0.05%
Maplight Therapeutics IncMPLT▼ Sold out−248.29K$5M0.04%
Amanat Acquisition CorpAMAN▲ New+375K$3.8M0.03%
Adicet Bio IncACET▼ Reduced 21%−250K$2.2M0.02%
Werewolf Therapeutics IncHOWL▼ Reduced 64%−4.29M$1.5M0.01%
Rezolute IncRZLT▲ Added 2.9%+265.04K$1.4M0.01%
GH Research PLCGHRS▼ Reduced 0.5%−39.88K$1.1M0.01%
Zai Lab LtdZLAB▲ Added 0.6%+36.27K$689.1K0.01%
Ovid Therapeutics IncOVID▼ Reduced 2.0%−213.03K$573.1K0.00%
Bioage Labs IncBIOA▲ Added 1.3%+21K$514.7K0.00%
Palatin Technologies IncPTN▼ Reduced 11%−7.88K$85K0.00%
Damora Therapeutics IncDMRA▲ Added 0.02%+392$10.2K0.00%

Holdings at the quarter's end

Peter Kolchinsky holdings, Q2 2026
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q1 2026
1Ascendis Pharma A/SASNDHealth Care23.8%$2.7B10.28M$266.729+ qtrs—
2Parabilis Medicines IncPBLS—6.88%$791.9M28.93M$27.371 qtrNew
3Rhythm Pharmaceuticals IncRYTMHealth Care6.43%$740.2M6.67M$111.039+ qtrsNo change
4Vaxcyte IncPCVXHealth Care5.80%$667M11.47M$58.139+ qtrsNo change
5Sionna Therapeutics IncSION—3.79%$435.7M9.91M$43.996 qtrsNo change
6Tyra Biosciences IncTYRA—3.39%$389.6M12.2M$31.949+ qtrsNo change
7Edgewise Therapeutics IncEWTXHealth Care2.96%$341M8.39M$40.639+ qtrs▼ Reduced 20%
8Newamsterdam Pharma CompanyNAMS—2.81%$323.7M9.55M$33.899+ qtrsNo change
9Hemab Therapeutics HoldingsCOAG—2.49%$286.8M7.81M$36.731 qtrNew
10Septerna IncSEPN—2.04%$234.3M7M$33.497 qtrsNo change
11Bicara Therapeutics IncBCAX—1.87%$215.4M7.26M$29.698 qtrsNo change
12Mineralys Therapeutics IncMLYS—1.80%$207.6M7.69M$26.989+ qtrsNo change
13GH Research PLCGHRS—1.78%$205.3M7.64M$26.889+ qtrs▼ Reduced 0.5%
14Disc Medicine IncIRON—1.56%$179.2M2.45M$73.146 qtrsNo change
15Spyglass Pharma IncSGP—1.55%$178.6M8.02M$22.262 qtrsNo change
16Artiva Biotherapeutics IncARTV—1.51%$174.2M17.96M$9.708 qtrs▲ Added 82%
17Janux Therapeutics IncJANX—1.49%$171.9M11.19M$15.369+ qtrsNo change
18Taysha Gene Therapies IncTSHA—1.39%$160.4M23.56M$6.819+ qtrsNo change
19BioCryst Pharmaceuticals IncBCRX—1.38%$158.3M15.83M$10.003 qtrsNo change
20Wave Life Sciences LtdWVE—1.36%$156.7M26.98M$5.819+ qtrsNo change
21
Nuvalent Incno ticker on file
—1.34%$153.9M1.25M$123.504 qtrs▼ Reduced 51%
22Abivax SAABVX · ADRHealth Care1.31%$150.9M1.13M$133.261 qtrNew
23Oruka Therapeutics IncORKAHealth Care1.29%$148M1.55M$95.171 qtrNew
24Climb Bio IncCLYM—1.28%$147.4M11.3M$13.049+ qtrsNo change
25Solid Biosciences IncSLDB—1.05%$120.2M12.04M$9.999+ qtrs▲ Added 29%
26Zai Lab LtdZLAB · ADR—0.95%$109.1M5.74M$19.002 qtrs▲ Added 0.6%
27Ars Pharmaceuticals IncSPRY—0.76%$87M10.86M$8.019+ qtrsNo change
28Xencor IncXNCR—0.74%$84.9M5.27M$16.102 qtrs▲ Added 7.7%
29Jade Biosciences IncJBIO—0.71%$81.6M3.67M$22.225 qtrsNo change
30Intellia Therapeutics IncNTLA—0.67%$76.6M4.53M$16.921 qtrNew
31LB Pharmaceuticals IncLBRX—0.62%$71.7M2.21M$32.464 qtrsNo change
32Definium Therapeutics IncDFTXHealth Care0.61%$70.6M1.5M$47.041 qtrNew
33Aclaris Therapeutics IncACRS—0.59%$67.3M12.72M$5.292 qtrs▲ Added 87%
344D Molecular TherapeuticsFDMT—0.58%$67.2M5.05M$13.309+ qtrsNo change
35Sana Biotechnology IncSANA—0.57%$65.4M18.75M$3.491 qtrNew
36Damora Therapeutics IncDMRA—0.54%$62.4M2.4M$26.012 qtrs▲ Added 0.02%
37Monopar Therapeutics IncMNPR—0.54%$61.8M667.21K$92.597 qtrsNo change
38Acumen Pharmaceuticals IncABOS—0.49%$56.1M20.99M$2.679+ qtrsNo change
39Geron CorpGERN—0.48%$54.8M42.81M$1.289+ qtrs▼ Reduced 33%
40Rezolute IncRZLT—0.43%$49.1M9.45M$5.203 qtrs▲ Added 2.9%
41Evommune IncEVMN—0.40%$46.4M3.49M$13.293 qtrsNo change
42Vor Biopharma IncVOR—0.38%$44.2M2.4M$18.419+ qtrs▼ Reduced 56%
43Century Therapeutics IncIPSC—0.38%$43.5M17.75M$2.452 qtrsNo change
44Aktis Oncology IncAKTS—0.37%$42.4M1.31M$32.232 qtrs▼ Reduced 13%
45Bioage Labs IncBIOA—0.36%$41M1.67M$24.512 qtrs▲ Added 1.3%
46C4 Therapeutics IncCCCC—0.33%$37.4M8M$4.673 qtrsNo change
47Mirum Pharmaceuticals IncMIRMHealth Care0.32%$37.3M318.55K$117.072 qtrsNo change
48Capricor Therapeutics IncCAPR—0.32%$36.3M1.51M$24.083 qtrsNo change
49Pepgen IncPEPG—0.31%$36.1M20.06M$1.809+ qtrsNo change
50Prelude Therapeutics IncPRLD—0.30%$34.5M6.48M$5.331 qtrNew
51Nkarta IncNKTX—0.27%$30.6M10.81M$2.839+ qtrsNo change
52Q32 Bio IncQTTB—0.26%$29.7M2.33M$12.741 qtrNew
53Anteris Technologies GlobalAVR—0.26%$29.6M3M$9.852 qtrsNo change
54Editas Medicine IncEDIT—0.25%$28.8M8.89M$3.241 qtrNew
55Ovid Therapeutics IncOVID—0.25%$28.2M10.5M$2.693 qtrs▼ Reduced 2.0%
56Assembly Biosciences IncASMB—0.24%$28M1.02M$27.484 qtrsNo change
57Alx Oncology Holdings IncALXO—0.23%$26.9M13.01M$2.072 qtrsNo change
58Benitec Biopharma IncBNTC—0.22%$24.8M1.85M$13.383 qtrsNo change
59Lenz Therapeutics IncLENZ—0.21%$23.7M4.18M$5.689+ qtrsNo change
60Lexeo Therapeutics IncLXEO—0.20%$23.3M5M$4.663 qtrsNo change
61Acrivon Therapeutics IncACRV—0.19%$21.8M12.23M$1.789+ qtrs▲ Added 47%
62Altimmune IncALT—0.17%$19.8M6.5M$3.041 qtrNew
63Karyopharm Therapeutics IncKPTI—0.16%$18.7M1.92M$9.772 qtrsNo change
64Bright Minds Biosciences IncDRUG—0.16%$18.6M265K$70.202 qtrsNo change
65Avalo Therapeutics IncAVTX—0.16%$18.5M1M$18.488 qtrs▲ Added 51%
66Onkure Therapeutics Inc-AOKUR—0.16%$18.2M4M$4.562 qtrsNo change
67Faeth Therapeutics IncFTH—0.16%$18.1M722.02K$25.001 qtrNew
68Aura Biosciences IncAURA—0.15%$17.8M2.5M$7.101 qtrNew
69Sab Biotherapeutics IncSABS—0.15%$17.2M4.4M$3.904 qtrsNo change
70Seaport Therapeutics IncSPTX—0.13%$15.2M700K$21.721 qtrNew
71Palisade Bio IncPALI—0.13%$14.9M7.12M$2.093 qtrsNo change
72Helix Acquisition CorpHLXC—0.12%$13.3M1.25M$10.642 qtrsNo change
73Waystar Holding CorpWAYTechnology0.09%$10.9M529.4K$20.533 qtrsNo change
74Equillium IncEQ—0.09%$9.9M3.1M$3.202 qtrsNo change
75Macrogenics IncMGNX—0.08%$8.6M1.86M$4.622 qtrsNo change
76
Perceptive Cap Solutionsno ticker on file
—0.07%$8.2M750K$10.889+ qtrsNo change
77Adicet Bio IncACET—0.07%$8.1M932.62K$8.649+ qtrs▼ Reduced 21%
78
Newamsterdam Pharma Co NV-27no ticker on file · WTS
—0.06%$7.1M333.33K$21.379+ qtrsNo change
79Corvus Pharmaceuticals IncCRVS—0.06%$6.7M450K$14.942 qtrsNo change
80Rani Therapeutics Holdings-ARANI—0.06%$6.5M8.5M$0.76043 qtrsNo change
81Jatt II Acquisition CorpJATT—0.05%$5.7M500K$11.361 qtrNew
82Amanat Acquisition CorpAMAN—0.03%$3.8M375K$10.161 qtrNew
83Werewolf Therapeutics IncHOWL—0.01%$859.3K2.39M$0.35999+ qtrs▼ Reduced 64%
84Palatin Technologies IncPTN—0.01%$670.3K62.12K$10.793 qtrs▼ Reduced 11%

By sector

Peter Kolchinsky portfolio by sector, Q2 2026
SectorShare of portfolioValuePositions
Health Care42.6%$4.9B8
Technology0.09%$10.9M1
No sector on file57.3%$6.6B75

Questions and answers

What did Peter Kolchinsky own in Q2 2026?

RA Capital Management's 13F for Q2 2026 lists 84 positions worth $11.5B. The largest: ASND (23.8%), PBLS (6.9%), RYTM (6.4%), PCVX (5.8%), SION (3.8%).

What did Peter Kolchinsky buy in Q2 2026?

The largest purchases, by the shares bought at the quarter-end price the filing implies: PBLS (new, $791.9M), COAG (new, $286.8M), ABVX (new, $150.9M), ORKA (new, $148M), ARTV (added, $78.6M), NTLA (new, $76.6M).

What did Peter Kolchinsky sell in Q2 2026?

The largest sales: DNTH (sold out, $219.2M), Nuvalent Inc (reduced, $159M), PRAX (sold out, $120.4M), SRPT (sold out, $84.9M), EWTX (reduced, $82.7M), SYRE (sold out, $81.8M).

When was this filing made?

RA Capital Management filed its 13F for the quarter ending Jun 30, 2026 on Aug 14, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Peter Kolchinsky portfolio, Q2 2026: RA Capital Management 13F holdings”, data as of 14 August 2026. https://funkfolio.com/gurus/peter-kolchinsky/2026-q2

Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Jun 30, 2026.

Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Jun 30, 2026, filed Aug 14, 2026. Changes compare share counts with the filing for Mar 31, 2026; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $11.5B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 9 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.